Selonabant

Selonabant
Clinical data
Other names	ANEB-001; ANEB001; V-24343; V24343
Drug class	Cannabinoid receptor antagonist; Cannabinoid CB1 receptor antagonist; Cannabinoid antidote
Identifiers
	IUPAC name N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide;
CAS Number	791848-71-0;
PubChem CID	68902536;
DrugBank	DB18908;
ChemSpider	128922145;
UNII	4RNU8C6XXW;
KEGG	D12875;
ChEMBL	ChEMBL5095165;
Chemical and physical data
Formula	C22H24ClF3N2O2
Molar mass	440.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)NC(=O)N1CC(C1)O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F;
	InChI InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1; Key:BNLYOVHLLDBOFZ-LJQANCHMSA-N;

Selonabant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB₁ receptor antagonist which is under development for the treatment of acute cannabinoid intoxication.^[1]^[2]^[3] It was also previously being developed to treat obesity, but development for this indication was discontinued.^[1] The drug is administered by intravenous infusion.^[1] It dramatically reduced the subjective effects of Δ⁹-tetrahydrocannabinol (THC) in a clinical trial.^[3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals.^[1]^[2] As of December 2024, it is in phase 2 trials.^[1]^[2]

Quick Facts Clinical data, Other names ...

[1]

[2]

[3]

Selonabant

See also

References

Wikiwand - on